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Introduction: Hemophilia A is an inherited, X-linked, recessive disorder caused by deficiency of functional plasma clotting
factor VIII (FVIII).  The disease, which has an incidence of 1 in 6000 male births, can be defined as mild, moderate, or
severe depending on the level of FVIII deficiency. Severe hemophilia A is characterized by spontaneous bleeding episodes
localized mainly in muscles (hematomas) and joints (hemarthroses). The therapy relies upon the occasional administration
of the deficient factor in the case of bleeding (“on demand” treatment), or regular factor VIII administration in order to
prevent bleedings (“prophylaxis”). End-stage chronic arthropathy and chronic liver disease are frequent complications of
most patients treated “on demand”. Clinical and pharmacoeconomic studies underline the economic gap existing between
the two different types of treatment of severe hemophilia A; however, the prophylaxis strategy started in Italy less than 20
years ago, so few studies are so far available, which compare the actual costs of both treatment modalities. Such studies
anyway are based on pharmacoeconomic evaluations of the prophylactic treatment as related to improvement of the pa-
tients’ quality of life (QoL), but do not compare the costs of prophylaxis with the real ones of the “on demand” treatment
and its long-term complications and HIV infections.
Methods: Our observational study aims to evaluate the cost utility of the two strategies, through an EQ-5D questionnaire
administered to 100 severe hemophilia A patients, divided into:
- adults (25-70 years) treated “on demand”, who, as a result of the disease and the type of treatment, developed chronic
arthropathy and hemophilia-related comorbidities;
- children and young adults (<25 years), who started replacement  prophylaxis when still children, and did not develop
such comorbidities. 
The evaluation of patients’ data from clinical charts allowed us to calculate the total costs of  primary prophylaxis and of
“on demand” treatment. 
By using the Markov model we were able to compare the hypothetical costs of both strategies based on the assumption that
patients on prophylactic treatment will not develop hemophilia-related complications, as patients treated on demand do.
Results and Conclusions: It seems likely that primary prophylaxis, initially more expensive, after some years improves
the Quality of Life of patients;  in the long distance primary prophylaxis might result a cost-effective strategy due to a si-
gnificant reduction of hemophilia-related comorbidities. Therefore, primary prophylaxis in Hemophiliacs might exert even
a reduction of the economic impact on regional health costs.
